News

Article

Clinical Quiz: Lifestyle and Nonpharmacological Interventions from ESC/EAS 2019 Dyslipidemia Guidelines

Our fourth and final quiz on the ESC/EAS 2019 guidelines on dyslipidemia spotlights lifestyle and nonpharmacological intervention recommendations.

HCPLive clinical quiz logo. | Credit: HCPLive

Credit: HCPLive

Few fields in cardiology have experienced the same level of change in recent years as lipidology. Driven by advances in pathophysiology as well as developments in pharmacological therapies, this change has further the role of guideline recommendations a critical component of educating clinicians.

While statin therapy has maintained its role as a mainstay in management of most lipid disorders as a result of their affordability, efficacy, and established safety profile, the aforementioned advances in pathophysiology, as well as the advent of new therapies, have redefined what is considered to be an optimal approach to the management of dyslipidemia for many patients.

In this clinical quiz, the final in our series of 4 quizzes based on the guideline document, we test your knowledge of lifestyle and nonpharmacological interventions from the 2019 European Society of Cardiology/European Atherosclerosis Society Guidelines for the Management of Dyslipidaemias: Lipid Modification to Reduce Cardiovascular Risk.

Which dietary change is recommended to specifically lower LDL-C levels?


Quizzes in this series:

Quiz 1: Lipid Management Principles from 2019 ESC/EAS Guidelines on Dyslipidemia

Quiz 2: Risk Assessment and Stratification from 2019 ESC/EAS Guidelines on Dyslipidemia

Quiz 3: Pharmacotherapy Recommendations from ESC/EAS 2019 Dyslipidemia Guidelines

Quiz 4: Lifestyle and Nonpharmacological Interventions from ESC/EAS 2019 Dyslipidemia Guidelines

Editor’s note: This quiz was generated through the use of AI tools.

References

  1. Menter A, Cordoro KM, Elmets CA, et al. Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients. J Am Acad Dermatol. 2020 Jan;82(1):161-201. doi: 10.1016/j.jaad.2019.08.049. Epub 2019 Nov 5. Erratum in: J Am Acad Dermatol. 2020 Mar;82(3):574. doi: 10.1016/j.jaad.2020.01.061. PMID: 31703821.
Related Videos
Will Herrington, MBBS, MD, MA: Empagliflozin Follow-up Data Informs Clinical Care for CKD
Jennifer Lai Yee, MD, PhD, MPH: Honing in on Sparsentan’s Benefit in Genetic FSGS
Highlighting Recent Therapies for Dermatologists, with James Del Rosso, DO
Ladan Zand, MD: Obinutuzumab Promising Option for Refractory, Primary FSGS
Rahul N. Khurana, MD: Phase 1 Results on Vamikibart for Uveitic Macular Edema | Image Credit: Northern California Retina Vitreous Associates
Sunir J. Garg, MD: | Image Credit: Wills Eye Hospital
James Del Rosso, DO: Discussing What’s New in the Medicine Chest for Dermatologists
What to Look Forward To at the Fall Clinical Dermatology Conference, with Raj Chovatiya, MD, PhD
Christine N. Kay, MD: Interim Data on ATSN-201 Shows Promise for XLRS | Image Credit: Vitreo Retinal Associates
© 2024 MJH Life Sciences

All rights reserved.